SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001689813-22-000079
Filing Date
2022-09-27
Accepted
2022-09-27 17:23:24
Documents
12
Period of Report
2022-09-27
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bhvn-20220927.htm   iXBRL 8-K 41207
  Complete submission text file 0001689813-22-000079.txt   179249

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bhvn-20220927.xsd EX-101.SCH 1920
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bhvn-20220927_lab.xml EX-101.LAB 23800
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bhvn-20220927_pre.xml EX-101.PRE 12702
6 EXTRACTED XBRL INSTANCE DOCUMENT bhvn-20220927_htm.xml XML 10538
Mailing Address 215 CHURCH STREET NEW HAVEN CT 06510
Business Address 215 CHURCH STREET NEW HAVEN CT 06510 203-404-0410
Biohaven Pharmaceutical Holding Co Ltd. (Filer) CIK: 0001689813 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38080 | Film No.: 221272186
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences